The company plans to commercialize drug delivery system (DDS) technology using self-assembling peptides such as A6K through licensing to major pharmaceutical companies and granting sales rights. This includes combining the technology with externally developed drug and therapeutic substance technologies, rather than pursuing pharmaceutical development independently.